All News

Conv3.jpg

EULAR 2024 - Day 1 Report

Jack Cush, MD

Wednesday was Day One at EULAR 2024 in Vienna. While the day was a slow start, the poster halls and auditoriums quickly filled with thousands of rheumatologists, eager to reunite at this international educational forum. Below are a few of my favorites from Day 1.

Read Article
hand stopping falling dominos

Can we prevent psoriatic arthritis?

Antoni Chan, MD, PhD

Psoriatic arthritis (PsA) can affect up to 30% of patients with psoriasis (PsO). Understanding the factors that predispose patients with PsO who progress to PsA is the first step in understanding how early interventions in PsO may augment the progression to PsA. At #EULAR2024, there are a few presentations on this topic that will help us understand this progression from PsO to PsA better.

Read Article
biosim.sign_.jpg

Humira Clobbers Biosimilars in Battle for Part D Coverage

Medpage Today

Just about every Medicare Part D prescription drug plan on offer this year covers the original version of adalimumab (Humira), whereas only about half will pay for any of the several biosimilar versions currently approved, researchers found.

Read Article
Synovial tissue specimens were processed for H&E-based semiquantitative synovitis quantification (KSS) in biopsies in PsA. KSS was significantly higher in cs/b-DMARDs resistant patients than naive PsA(p<0.0001) and PsA in remission/LDA (p<0.0001). KSS directly correlated with… https://t.co/cHIw8zRByK https://t.co/vppmG7JwC8

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)
In a Swedish-Danish cohort study on patients with PsA, treatment with TNFi was associated with a small increased risk of NMSC and with non-significant numeric risk increases for both BCC and SCC compared with bDMARD naïve #EULAR2024 Abstract 0150 @RheumNow https://t.co/vC4pgSKmfY

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)
Can we prevent psoriatic arthritis? Highlights from #EULAR2024 that help us understand this topic better @RheumNow https://t.co/E8Wy8FH4oU

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)

200 millions pts PSO 1st line, Reduction risk PsA: IL 12-23 37% & IL-23 39% vs. TNFi 2nd line ttmt, IL12-23i 32% & IL-23i 31% IL-23i 47% lower proba PsA than IL-17i 3 & 5 yrs Can't exclude some channeling bias, but that's a big signal! @RheumNow OP0010 #EULAR2024 #EULARBest

Aurelie Najm AurelieRheumo ( View Tweet)

A potentially notable association between TNFi in PsA and an increased risk of ischemic heart diseases and heart failure compared to IL-17i treatment. Limitations of the study noted. This may be due to patient selection and channeling of patients to the TNFi group and more… https://t.co/Q2LotHZwjQ https://t.co/uwl6vBIMsb

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)
💊 Difficult-to-treat #SpA & #PsA 🤔 What are the challenges in assessing persistently active disease? 🗣️ Vinod Chandran takes us through the pearls and pitfalls in assessing D2T disease 🌎 Great to see #comorbidities highlighted @RheumNow #EULAR2024 https://t.co/x4jUTOC3li

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
Areas to consider in difficult to manage PsA and research agenda #EULAR2024 Chandran V @RheumNow https://t.co/sp4tkAivLa

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)
Significant proportion of patients in PsA do not achieve remission across the domains. This can be due to disease heterogeneity, domain differences, comorbidities. There is a need to study the use of combination ts and bDMARDs. Difficult to Manage PsA session #EULAR2024 Ribeiro,… https://t.co/Wt3jgtIR9N https://t.co/VzCApikqek

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)
Grappa - distinguish D2T from complex to manage - objective signs of inflammation imaging - US or MRI not lab markers @rheumnow #EULAR2024

Peter Nash drpnash ( View Tweet)

almost half PsA patients have 3 pr more co-morbidities and 67% of those surveyed do not think rheumos should not manage them - when did we stop being physicians ? @rheumnow #EULAR2024

Peter Nash drpnash ( View Tweet)

« difficult to treat PsA » how mich combination obesity, non-inflammatory MSK pain, fibromyalgia and depression making assessment tricky and risk of rattling through therapies fast! @rheumnow #EULAR2024

Peter Nash drpnash ( View Tweet)

RISK OF PsA IN PATIENTS WITH PsO UNDERGOING bDMARDs GLOBAL POPULATION STUDY (TRINETX) 870,000 PsO pts without PsA treated with bDMARDS - Il12/23i and Il23i. 30-37% lower PsA developed than comparators @rheumnow #EULAR2024

Peter Nash drpnash ( View Tweet)

OP0031 (2024) COMPARATIVE ANALYSIS OF TNF INHIBITORS AND IL17 INHIBITORS IN PSORIATIC ARTHRITIS: EXPLORING CARDIOVASCULAR OUTCOMES signif absolute risk difference 3 % ischaemic heart disease 2 % heart failure TNFi vs IL17i @rheumnow #EULAR2024

Peter Nash drpnash ( View Tweet)

Grappa difficult to treat PsA meeting - SLR, Patient & rheumo survey, definition eg - fail 1 csDMARD & 2 bDMARDs different MOA - names matter suggest ditch « difficult » for « refractory » @rheumnow #EULAR2024

Peter Nash drpnash ( View Tweet)

National Psoriasis Foundation’s 2019 Annual Survey of 1,570 #PSO pts found among 801 w/ PsA most (59.6%) report unacceptable levels of disease activity, which is associated with increased prevalence of depression and limitations in social participation. https://t.co/HtWcAhZ6Zu https://t.co/pdC4IjIxmj

Links:

Dr. John Cush RheumNow ( View Tweet)
Israeli study shows the prevalence of Psoriatic arthritis has tripled since 2006 - 2006: 0.073% - 2016: 0.165% - 2022: 0.221% ~2 fold higher rate if Jewish, High SES, Obese https://t.co/RMWcIZvfjb https://t.co/9H6sauSEZK https://t.co/Fhj64pADdJ

Links:

Dr. John Cush RheumNow ( View Tweet)
Full read review on Psoriasis Flares; risks: - mechanical stress - infections -dysbiosis -drugs (Lithium, B-blockers, HCQ, tetracyclines, ACEi, IFN) - environment(smoking, obesity) -lifestyle - stress - hormonal/metabolic https://t.co/WfCzcG9XNM https://t.co/ZNeKxjtHSA https://t.co/sJDoSfFOL4

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×